SCHEMBL674194

SCHEMBL674194

Nc1cccnc1C(=O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
GAA P10253 1/20 0.53
KMT2A Q03164 2/20 0.52
HTT P42858 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PBRM1 Q86U86 1/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 2/20 0.46
TLR7 Q9NYK1 1/20 0.46
KDM4E B2RXH2 1/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
BLM P54132 1/20 0.44
AGER Q15109 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPK13 O15264 1/20 0.44
MAPK12 P53778 1/20 0.44
MAPK11 Q15759 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30821243 1.00 MAPT (0.53) MAPTGAAKMT2AHTTHSD17B10
SCHEMBL20558075 0.86 GRM4 (0.49) MAPTGAAALDH1A1TLR7KDM4E
SCHEMBL128343 0.80 KDM4E (0.61) MAPTGAAALDH1A1TLR7KDM4E
SCHEMBL30504303 0.79 ATR (0.57) MAPTGAAKMT2AHTTHSD17B10
SCHEMBL187899 0.79 ALDH1A1 (0.55) MAPTGAAKMT2AMEN1ALDH1A1
SCHEMBL5682288 0.79 ATR (0.57) MAPTGAAKMT2AHTTHSD17B10
SCHEMBL2280224 0.79 KDM4E (0.59) MAPTGAAALDH1A1TLR7KDM4E
SCHEMBL29262306 0.79 KDM4E (0.59) MAPTGAAKMT2AMEN1ALDH1A1
SCHEMBL17263069 0.78 KMT2A (0.52) MAPTKMT2AHTTMEN1ALDH1A1
SCHEMBL20385460 0.78 KMT2A (0.52) MAPTGAAKMT2AHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10398706-B2 Heteroaryldiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2019-09-03 US disclosed
US-20180193352-A1 HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2018-07-12 US disclosed
US-20180193352-A1 HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2018-07-12 US disclosed
WO-2018129287-A1 HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2018-07-12 WO disclosed
US-20150190504-A1 WOUND HEALING KINETIC CONCEPTS, INC. 2015-07-09 US disclosed
US-8957076-B2 Wound healing SYSTAGENIX WOUND MANAGEMENT (US), INC. (US) 2015-02-17 US disclosed
US-8063052-B2 Wound healing SYSTAGENIX WOUND MANAGEMENT (US), INC. (US) 2011-11-22 US disclosed
US-20100099622-A1 WOUND HEALING SYSTAGENIX WOUND MANAGEMENT (US), INC. (US) 2010-04-22 US disclosed
US-20090170910-A1 WOUND HEALING KCI USA, INC. 2009-07-02 US disclosed
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US disclosed
EP-1660087-A2 QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-31 EP disclosed
WO-2006028836-A1 WOUND HEALING ETHICON, INC. (US) 2006-03-16 WO disclosed
US-6919336-B2 Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of IL-1 and TNF NOVARTIS AG (CH) 2005-07-19 US disclosed
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US disclosed
WO-2005009967-A2 QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-03 WO disclosed
US-20040097731-A1 Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1and tnf NOVARTIS AG (CH) 2004-05-20 US disclosed
US-4207322-A 6-Aryl-s-triazolo-(4,3-alpha)-pyrido-(2,3-f)-(1,4)-diazepines DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1980-06-10 US disclosed
US-4110455-A 6-ARYL-S-TRIAZOLO-(4,3-A)-PYRIDO-(2,3-F)-1,4-DIAZEPINES DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1978-08-29 US disclosed
US-4012397-A 2-Benzoyl-3-amino-pyridines DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) 1977-03-15 US disclosed
US-3969361-A 2-Benzoyl-3-amino-pyridines DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) 1976-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10398706-B2 Heteroaryldiazepine derivatives as RSV inhibitors CYP3A5, CYP3A43, CYP3A4 MAPT 3236/4885GAA 1774/4885KMT2A 649/4885
US-20100099622-A1 WOUND HEALING MAPK1, MAPK3, MAPK4 MAPT 3256/4885GAA 4803/4885KMT2A 4281/4885
US-20040097731-A1 Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1and tnf TNF, NFKBIA, IL1A MAPT 2379/4885GAA 1202/4885KMT2A 1573/4885
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase FLT3, ABL1, FES MAPT 472/4885GAA 4452/4885KMT2A 1469/4885
US-20090170910-A1 WOUND HEALING MAPK1, MAPK3, MAPK4 MAPT 3256/4885GAA 4803/4885KMT2A 4281/4885
US-20150190504-A1 WOUND HEALING MAPK1, MAPK3, MAPK4 MAPT 3256/4885GAA 4803/4885KMT2A 4281/4885
US-20180193352-A1 HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS CYP3A5, CYP3A43, CYP3A4 MAPT 3236/4885GAA 1774/4885KMT2A 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.